{"filing":{"accession_number":"0001193125-26-364210","cik":"0001984086","ticker":"SEPN","company_name":"Septerna, Inc.","form":"8-K","filing_date":"2026-08-25","report_date":"2026-08-22","primary_document":"d172697d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526364210/d172697d8k.htm"},"events":[{"id":29344,"run_id":26862,"accession_number":"0001193125-26-364210","anchor_item_number":"8.01","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Septerna appointed Rajiv Patni, M.D., as Chief Medical Officer effective August 24, 2026. Dr. Patni brings 25+ years of biopharmaceutical executive experience, including prior roles as CEO and Chief R\u0026D Officer, and a successful track record guiding investigational medicines through regulatory approvals. This appointment is material to the company's clinical development strategy and pipeline advancement.","company_name":"Septerna, Inc.","ticker":"SEPN","filing_date":"2026-08-25","form":"8-K","submitted_at":null,"items":[{"id":31595,"accession_number":"0001193125-26-364210","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Rajiv Patni, M.D., as Chief Medical Officer of Septerna, Inc. The press release emphasizes his 25+ years of experience, successful track record guiding investigational medicines through regulatory approvals, and leadership role in advancing the company's clinical programs. This is a material executive appointment at a clinical-stage biotechnology company where the CMO role is critical to clinical development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:16:39.399261+00:00","company_name":"","ticker":null,"filing_date":""},{"id":31596,"accession_number":"0001193125-26-364210","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Rajiv Patni, M.D., as Chief Medical Officer effective August 24, 2026. The press release emphasizes his 25+ years of biopharmaceutical executive experience, successful track record guiding medicines through regulatory approvals, and prior roles as CEO and Chief R\u0026D Officer at other companies. For a clinical-stage biotech company, the appointment of a CMO with this caliber of experience is material to investors assessing the company's ability to advance its clinical pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:16:39.399261+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":31595,"accession_number":"0001193125-26-364210","item_number":"7.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Rajiv Patni, M.D., as Chief Medical Officer of Septerna, Inc. The press release emphasizes his 25+ years of experience, successful track record guiding investigational medicines through regulatory approvals, and leadership role in advancing the company's clinical programs. This is a material executive appointment at a clinical-stage biotechnology company where the CMO role is critical to clinical development strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:16:39.399261+00:00","company_name":"Septerna, Inc.","ticker":"SEPN","filing_date":"2026-08-25"},{"id":31596,"accession_number":"0001193125-26-364210","item_number":"8.01","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Rajiv Patni, M.D., as Chief Medical Officer effective August 24, 2026. The press release emphasizes his 25+ years of biopharmaceutical executive experience, successful track record guiding medicines through regulatory approvals, and prior roles as CEO and Chief R\u0026D Officer at other companies. For a clinical-stage biotech company, the appointment of a CMO with this caliber of experience is material to investors assessing the company's ability to advance its clinical pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-25T12:16:39.399261+00:00","company_name":"Septerna, Inc.","ticker":"SEPN","filing_date":"2026-08-25"}]}